期刊文献+

阿司匹林抵抗与COX-2基因G765C单核苷酸多态性临床研究 被引量:2

下载PDF
导出
摘要 目的探讨脑梗死患者二级预防中阿司匹林抵抗现象及其与COX-2基因G765C单核苷酸多态性的相关研究。方法选择急性脑梗死患者126例、有高危脑卒中风险但非脑梗死患者80例及健康志愿者30例,分别以花生四烯酸(arachidonic acid,AA)和二磷酸腺苷(adenosine diphosphate,ADP)作为诱导剂,采用比浊法测定血小板聚集率;三组均以多聚酶链式反应结合限制性内切酶片段长度多态分析方法,检测COX-2基因G765C单核苷酸多态性。结果 126例脑梗死患者中有阿司匹林抵抗39例(30.95%),阿司匹林半抵抗13例(10.32%),阿司匹林敏感74例(58.73%)。非脑梗死组及健康对照组未发现阿司匹林抵抗现象的存在。脑梗死组患者COX-2基因G765C的基因型频率(GG型95.87%,GC型4.13%,CC型0%),与非脑梗死组基因型频率(GG型96.25%,GC型3.75%,CC型0%)和健康对照组基因型频率(GG型96.67%,GC型3.33%,CC型0%)比较无显著性差异(P>0.05)。纯合或者杂合C等位基因携带者在阿司匹林抵抗、半抵抗与敏感组中比较均无显著性差异(P>0.05)。结论脑梗死患者阿司匹林抵抗发生率高,COX-2基因G765C单核苷酸多态性与阿司匹林抵抗的发生无明显关系。
机构地区 瑞安市人民医院
出处 《浙江实用医学》 2013年第3期157-159,共3页 Zhejiang Practical Medicine
  • 相关文献

参考文献6

  • 1Antithrombotic Trialists,Collaboration Collaborative meta - analysis ofrandomized trials of antiplatelet thery for prevention of death,my-ocardial infarction and stroke in high risk patients.BMJ,2002,324:71.
  • 2T. Goodman, P. Sharma,A.Ferro, et al. The genetics of aspirin resis-tance .Int J Clin Pmct,2007,61 : 826.
  • 3Timothy Goodman, Albert Ferro, Pankaj Sharmal. Hiarmacogenetics ofaspirin resistance: a comprehensive systematic review. Br J Clin Hiar-macol,2008,66 ; 222.
  • 4陈伟群,王新德.全国第五届脑血管病学术会议纪要[J].中华神经科杂志,2000,33(4):59-61. 被引量:98
  • 5Gum P A, Kottke - Marchant K, Welsh P A, et al. A prospective,blinded determination of the natural history of aspirin resistance amcngstable patients with cardiovascular disease.J Am Coll Cardiol,20C8,41:961.
  • 6Sanderson S,Emery J,Baglin T, et al. Narrative review: aspirin resis-tance and its clinical implications. Ann Intern Med, 2005,142 : 370.

共引文献97

同被引文献81

  • 1赵勇,王建春,孙慧,王传霞,李元堂,尹承华,张杰,邵建华.环氧化酶-2基因-765G>C多态性与老年代谢综合征患者阿司匹林抵抗无关[J].中国分子心脏病学杂志,2011,11(3):164-168. 被引量:4
  • 2全锦花,张新超,蔡剑平,何青,许锋,戴大鹏.急性冠状动脉综合征患者血小板内皮细胞粘附分子1基因多态性分析[J].中国动脉硬化杂志,2007,15(2):120-124. 被引量:2
  • 3Atique S,Bauman C,Seiji R,et al. Aspirin resistance and athero- thrombosis[J]. Braz J Cardiovasc Surg, 2007,22 : 96-103.
  • 4Antithromhotic Trialists(ATT) Collaboration, Batgent C, Black- well L,et al. Aspirin in the pcimary and accondary prevention of vascular disease;collaborative meta-analysis of individual partici- pant data from randomized trials[J]. Lancet, 2009,373: 1849- 1860.
  • 5Berger JS,Kranta M J, Kittelson JM, et a l. Aspirin for the pre- vention of cardiovascular events in patients with peripheral arter- y disease: a meta-analysis of randomized trials [J]. JAMA, 2009, 301(18) : 1909-1919.
  • 6Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update:a report from the American Heart Association [J]. Circulation, 2011, 123(4) : 18-209.
  • 7Hankey GJ, Eikelboom JW. Aspirin Resistance [J]. Lancet, 2006, 367(9510): 606- 617.
  • 8Goodman T,Sharma F. The genetics of aspirin resistance[J]. Int J Clin Pract,2007,61 :826.
  • 9Timothy Goodman, lbert Ferro, ankaj Sharmal. Pharmacogenet- its of aspirin resistance:a comprehensive systematic review[J]. Br J Clin Pharmacol, 2008,66 : 222.
  • 10Kohsaka S,Volcik KA, Folsom AR,et al. Increasedrisk of inci- dent stroke associated with the cyclooxygenase 2 (COX-2) G- 765C polymorphism in Afrcan-Amreicans: the atherosclerosis risk in communities study[J]. Atherosclerosis, 2008,196 : 926- 930.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部